ROCKAWAY, N.J., Oct. 23, 2024 (GLOBE NEWSWIRE) -- electroCore, Inc. (Nasdaq: ECOR), a commercial-stage bioelectronic medicine and wellness company, today announced that it will report financial results for the third quarter ended September 30, 2024, after the close of the market on Wednesday, November 13, 2024. Management will host a conference call and webcast at 4:30 PM EST to discuss the financial results and answer questions.
Wednesday, November 13, 4:30 PM EST
Dial-In: 877-407-8835 / +1 201-689-8779
Conference ID: 13744121
Webcast: electroCore Earnings Webcast
About electroCore, Inc.
electroCore, Inc. is a commercial stage bioelectronic medicine and wellness company dedicated to improving health through its non-invasive vagus nerve stimulation (“nVNS”) technology platform. Our focus is the commercialization of medical devices for the management and treatment of certain medical conditions and consumer product offerings utilizing nVNS to promote general wellbeing and human performance in the United States and select overseas markets.
For more information, visit www.electrocore.com.
Contact:
ECOR Investor Relations
(973) 302-9253
This email address is being protected from spambots. You need JavaScript enabled to view it.
| Last Trade: | US$4.74 |
| Daily Change: | -0.28 -5.58 |
| Daily Volume: | 32,575 |
| Market Cap: | US$35.930M |
September 05, 2025 September 03, 2025 August 06, 2025 | |
C4 Therapeutics is pioneering a new class of small-molecule drugs that selectively destroy disease-causing proteins via degradation using the innate machinery of the cell. This targeted protein degradation approach offers advantages over traditional drugs, including the potential to treat a wider range of diseases...
CLICK TO LEARN MORE
Recursion Pharmaceuticals is a clinical stage TechBio company leading the space by decoding biology to industrialize drug discovery. Enabling its mission is the Recursion OS, a platform built across diverse technologies that continuously expands one of the world’s largest....
CLICK TO LEARN MORE
